Paul Hodgkins
Vertex Pharmaceuticals
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul Hodgkins.
Journal of the American Academy of Child and Adolescent Psychiatry | 2012
Jalpa A. Doshi; Paul Hodgkins; Jennifer Kahle; Vanja Sikirica; Michael J. Cangelosi; Juliana Setyawan; M. Haim Erder; Peter J. Neumann
OBJECTIVE Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent mental disorders in children in the United States and often persists into adulthood with associated symptomatology and impairments. This article comprehensively reviews studies reporting ADHD-related incremental (excess) costs for children/adolescents and adults and presents estimates of annual national incremental costs of ADHD. METHOD A systematic search for primary United States-based studies published from January 1, 1990 through June 30, 2011 on costs of children/adolescents and adults with ADHD and their family members was conducted. Only studies in which mean annual incremental costs per individual with ADHD above non-ADHD controls were reported or could be derived were included. Per-person incremental costs were adjusted to 2010 U.S. dollars and converted to annual national incremental costs of ADHD based on 2010 U.S. Census population estimates, ADHD prevalence rates, number of household members, and employment rates by age group. RESULTS Nineteen studies met the inclusion criteria. Overall national annual incremental costs of ADHD ranged from
BMC Pediatrics | 2012
Suzanne McCarthy; Lynda Wilton; Macey L. Murray; Paul Hodgkins; Philip Asherson; Ian C. K. Wong
143 to
Clinical Gastroenterology and Hepatology | 2013
Kamyar Shahedi; Garth Fuller; Roger Bolus; Erica R. Cohen; Michelle Vu; Rena Shah; Nikhil Agarwal; Marc Kaneshiro; Mary A. Atia; Victoria Sheen; Nicole Kurzbard; Martijn G. van Oijen; Linnette Yen; Paul Hodgkins; M. Haim Erder; Brennan M. Spiegel
266 billion (B). Most of these costs were incurred by adults (
Clinical Therapeutics | 2011
Paul Hodgkins; Rahul Sasané; Willemijn M. Meijer
105 B-
Current Medical Research and Opinion | 2010
Laura Christensen; Rahul Sasané; Paul Hodgkins; Carolyn Harley; Srinivas Tetali
194 B) compared with children/adolescents (
Journal of Attention Disorders | 2012
Philip Asherson; Ron Akehurst; J. J. Sandra Kooij; Michael Huss; Kathleen Beusterien; Rahul Sasané; Shadi Gholizadeh; Paul Hodgkins
38 B-
Psychological Medicine | 2015
Susan Young; Duncan Moss; Ottilie Sedgwick; Moshe Fridman; Paul Hodgkins
72 B). For adults, the largest cost category was productivity and income losses (
Clinical Gastroenterology and Hepatology | 2013
Erica R. Cohen; Garth Fuller; Roger Bolus; Rusha Modi; Michelle Vu; Kamyar Shahedi; Rena Shah; Mary A. Atia; Nicole Kurzbard; Victoria Sheen; Nikhil Agarwal; Marc Kaneshiro; Linnette Yen; Paul Hodgkins; M. Haim Erder; Brennan M. Spiegel
87 B-
Value in Health | 2012
James Signorovitch; Vanja Sikirica; M. Haim Erder; Jipan Xie; Mei Lu; Paul Hodgkins; Keith A. Betts; Eric Q. Wu
138 B). For children, the largest cost categories were health care (
Journal of Attention Disorders | 2012
J. J. Sandra Kooij; Michael Huss; Philip Asherson; Ron Akehurst; Kathleen Beusterien; Alexis French; Rahul Sasané; Paul Hodgkins
21 B-
